Literature DB >> 21865159

Solution structure of the soluble receptor for advanced glycation end products (sRAGE).

Zsuzsa Sárkány1, Teemu P Ikonen, Frederico Ferreira-da-Silva, Maria João Saraiva, Dmitri Svergun, Ana Margarida Damas.   

Abstract

The receptor for advanced glycation end products (RAGE) is a multiligand cell surface receptor involved in various human diseases, as it binds to numerous molecules and proteins that modulate the activity of other proteins. Elucidating the three-dimensional structure of this receptor is therefore most important for understanding its function during activation and cellular signaling. The major alternative splice product of RAGE comprises its extracellular region that occurs as a soluble protein (sRAGE). Although the structures of sRAGE domains were available, their assembly into the functional full-length protein remained unknown. We observed that the protein has concentration-dependent oligomerization behavior, and this is also mediated by the presence of Ca(2+) ions. Moreover, using synchrotron small angle x-ray scattering, the solution structure of human sRAGE was determined in the monomeric and dimeric forms. The model for the monomer displays a J-like shape, whereas the dimer is formed through the association of the two N-terminal domains and has an elongated structure. These results provide insights into the assembly of the RAGE homodimer, which is essential for signal transduction, and the sRAGE:RAGE heterodimer that leads to blockage of the receptor signaling, paving the way for the design of therapeutic strategies for a large number of different pathologies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865159      PMCID: PMC3199498          DOI: 10.1074/jbc.M111.223438

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.

Authors:  Hongliang Zong; Angelina Madden; Micheal Ward; Mark H Mooney; Christopher T Elliott; Alan W Stitt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

3.  Internalization of the receptor for advanced glycation end products (RAGE) is required to mediate intracellular responses.

Authors:  Natalia Sevillano; María D Girón; Mercedes Salido; Alberto M Vargas; José Vilches; Rafael Salto
Journal:  J Biochem       Date:  2008-10-11       Impact factor: 3.387

4.  Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation.

Authors:  M M Sousa; S D Yan; D Stern; M J Saraiva
Journal:  Lab Invest       Date:  2000-07       Impact factor: 5.662

5.  N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.

Authors:  T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 6.  S100 proteins: structure, functions and pathology.

Authors:  Claus W Heizmann; Günter Fritz; Beat W Schäfer
Journal:  Front Biosci       Date:  2002-05-01

7.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.

Authors:  M T Goova; J Li; T Kislinger; W Qu; Y Lu; L G Bucciarelli; S Nowygrod; B M Wolf; X Caliste; S F Yan; D M Stern; A M Schmidt
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Structural basis for ligand recognition and activation of RAGE.

Authors:  Michael Koch; Seth Chitayat; Brian M Dattilo; Andre Schiefner; Joachim Diez; Walter J Chazin; Günter Fritz
Journal:  Structure       Date:  2010-10-13       Impact factor: 5.006

9.  The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding.

Authors:  Hajeung Park; Floyd G Adsit; Jeffrey C Boyington
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

10.  Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction.

Authors:  Shigeyuki Matsumoto; Takuya Yoshida; Hiroko Murata; Shusaku Harada; Naoko Fujita; Shota Nakamura; Yasuhiko Yamamoto; Takuo Watanabe; Hideto Yonekura; Hiroshi Yamamoto; Tadayasu Ohkubo; Yuji Kobayashi
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

View more
  16 in total

1.  NMR characterization of the C-terminal tail of full-length RAGE in a membrane mimicking environment.

Authors:  Valentina Borsi; Linda Cerofolini; Marco Fragai; Claudio Luchinat
Journal:  J Biomol NMR       Date:  2012-09-22       Impact factor: 2.835

2.  Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.

Authors:  Casey M Rebholz; Brad C Astor; Morgan E Grams; Marc K Halushka; Mariana Lazo; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

Review 3.  Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications.

Authors:  Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

4.  Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome.

Authors:  Simina-Ramona Selejan; Dominik Linz; Muriel Mauz; Mathias Hohl; Anh Khoa Dennis Huynh; Thimoteus Speer; Jan Wintrich; Andrey Kazakov; Christian Werner; Felix Mahfoud; Michael Böhm
Journal:  Basic Res Cardiol       Date:  2022-07-14       Impact factor: 12.416

5.  Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling.

Authors:  Jing Xue; Michaele Manigrasso; Matteo Scalabrin; Vivek Rai; Sergey Reverdatto; David S Burz; Daniele Fabris; Ann Marie Schmidt; Alexander Shekhtman
Journal:  Structure       Date:  2016-08-11       Impact factor: 5.006

6.  Stable RAGE-heparan sulfate complexes are essential for signal transduction.

Authors:  Ding Xu; Jeffrey H Young; Juno M Krahn; Danyin Song; Kevin D Corbett; Walter J Chazin; Lars C Pedersen; Jeffrey D Esko
Journal:  ACS Chem Biol       Date:  2013-05-28       Impact factor: 5.100

Review 7.  Is RAGE still a therapeutic target for Alzheimer's disease?

Authors:  Richard J Deane
Journal:  Future Med Chem       Date:  2012-05       Impact factor: 3.808

8.  Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange.

Authors:  Ewa Sitkiewicz; Krzysztof Tarnowski; Jarosław Poznański; Magdalena Kulma; Michal Dadlez
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

9.  Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products.

Authors:  Pavle S Milutinovic; Judson M Englert; Lauren T Crum; Neale S Mason; Lasse Ramsgaard; Jan J Enghild; Louis J Sparvero; Michael T Lotze; Tim D Oury
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

10.  RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA.

Authors:  Cherilyn M Sirois; Tengchuan Jin; Allison L Miller; Damien Bertheloot; Hirotaka Nakamura; Gabor L Horvath; Abubakar Mian; Jiansheng Jiang; Jacob Schrum; Lukas Bossaller; Karin Pelka; Natalio Garbi; Yambasu Brewah; Jane Tian; ChewShun Chang; Partha S Chowdhury; Gary P Sims; Roland Kolbeck; Anthony J Coyle; Alison A Humbles; T Sam Xiao; Eicke Latz
Journal:  J Exp Med       Date:  2013-09-30       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.